兔抗ERBB2多克隆抗体

Background:

The ErbB2 (HER2) proto-oncogene encodes a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity. While ErbB2 lacks an identified ligand, ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB family members. Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers. Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase. ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy. Phosphorylation of the kinase domain residue Tyr877 of ErbB2 (homologous to Tyr416 of pp60c-Src) may be involved in regulating ErbB2 biological activity. The major autophosphorylation sites in ErbB2 are Tyr1248 and Tyr1221/1222; phosphorylation of these sites couples ErbB2 to the Ras-Raf-MAP kinase signal transduction pathway.

Applications:

ELISA, WB, IHC

Name of antibody:

ERBB2

Immunogen:

Synthetic peptide of human ERBB2

Full name:

erb-b2 receptor tyrosine kinase 2

Synonyms:

NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu

SwissProt:

P04626

ELISA Recommended dilution:

5000-10000

IHC positive control:

Human brain and human ovarian cancer

IHC Recommend dilution:

20-100

WB Predicted band size:

138 kDa

WB Positive control:

231 and Hela cell lysates

WB Recommended dilution:

200-1000